Investor Presentaiton
US Mesh litigation - Overview of financial impact
P&L - overview of special items related to the Mesh
litigation
Balance
Assets
Restricted cash, DKKbn
Cash flow
Actual/Expected cash flow, DKKbn
Actual cash flow ☐ Expected cash flow
13/14-
17/18
18/19 19/20 20/21 21/22
YTD
22/23
EBIT (before
special items)
5,556
5,854
6,355 6,910
5,131
Special items
(Mesh)
-4,750
-400
-200
-300
-200
Other special
items*
-171
195
0.1
EBIT
5,156
5,854
6,155
6,439
5,126
0.5
0.5
0.0
0.0
0.0
0.0 0.0 0.0
14/15 15/16 16/17 17/18 18/19 19/20 20/21 21/22 YTD
22/23
Liabilities
EBIT % (before
special items)
31
32
33
31
28
Total liability, DKKbn
EBIT %
29
32
32
29
28
Other payables
Provision
0.7
•
A total of DKK 6,350 million (DKK 5,850 million net of insurance coverage) has
been provisioned and is considered sufficient
2.4
3.3
•
Coloplast now considers the MDL cases closed. Any future cases will be
considered part of the normal course of the International Urology business
1.2
0.1
0.1
0.3
1.1
0.3
0.4
0.5
0.1
0.3 0.2 0.2 0.2
0.1
14/15 15/16 16/17 17/18 18/19 19/20 20/21 21/22 YTD
22/23
* Other special items income of DKK 195 million YTD 2022/23 includes an income of DKK 244
million related to a reversal of the provision regarding Atos Medical US billing compliance, and DKK
49 million related to integration costs for the Atos Medical acquisition. Other special items of DKK
171 million in FY 2021/22 relate to the Atos Medical acquisition (transaction and integration costs).
70
0.5
0.3
1.8
1.6
0.5
0.4
0.2 0.2
22/23 &
beyond
0.3
0.4
0.1
13/14 14/15 15/16 16/17 17/18 18/19 19/20 20/21 21/22 22/23
• Insurance coverage of DKK 500m
received in 2013/14 and 2014/15
ColoplastView entire presentation